Free Trial
Want deep insights into your competitors & competitive landscape? Try Patsnap Eureka!

Top 10 New Entrants companies in PCSK9 Inhibitors
by Most Patent Filing In 3 Years in the world in 2018

The PCSK9 Inhibitors top 10 is Discovery PatSnap’ annual ranking of the top 10 Most Patent Filing In 3 Years PCSK9 Inhibitors New Entrants in the world. Discovery has identified the top key players, startups & unicorns, fast-growings, news entrants in 2018, ranking from differnt perspectives, including patent filing intensity, academic research capability, news media heat. The company list is generated from various data types.
The PCSK9 inhibitors are a class of injectable drugs approved in 2015 that have been shown to dramatically lower LDL cholesterol levels -- by up to 60% in some cases -- when combined with a statin.. PCSK9 inhibitors are monoclonal antibodies (MABs), a type of biologic drug. They bind to and inactivate an enzyme in the liver called proprotein convertase subtilisin kexin 9 (PCSK9).
#
Company Name
Region
Tech Topics
Total
1
Switzerland
Medicine,Health care,Drug,
...[+2]
Patent: 11
2
California, United States
Health care,Biopharmaceutical,TUMOR NECROSIS FACTOR BLOCKER,
...[+2]
Patent: 10
3
Hovedstaden, Denmark
Insulin,Health care,Haemophilia,
...[+2]
Patent: 10
4
Canada
Patent: 4
5
Guangdong Sheng, China
Patent: 3
6
Pokka Corp.
Aichi, Japan
Food industry,Soft drink,Fountain,
...[+1]
Patent: 2
7
Jiangsu Sheng, China
Patent: 1
8
Sichuan Sheng, China
Patent: 1
9
Tokyo, Japan
Food industry,Microbrewery,Biopesticide,
...[+2]
Patent: 1
10
Hunan Sheng, China
National security,BCG vaccine,HIV vaccine,
...[+2]
Patent: 1
Page generation time: May 17 2025